Zhuhai Rundu Pharmaceutical Co., Ltd.

002923

CNE1000033G8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
10.63 ^CNY	-0.37%		-3.36%	-13.86%

May. 20	Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Final Cash Dividend on A Shares for 2023, Payable on 31 May 2024	CI
Apr. 27	Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Zhuhai Rundu Pharmaceutical Co., Ltd. Proposes Final Cash Dividend on A Share for 2019

April 17, 2020 at 03:32 pm EDT

Zhuhai Rundu Pharmaceutical Co., Ltd. announced the profit distribution proposal on A share for 2019. Final Cash dividend per 10 shares (tax included) is CNY 4.00000000.

Latest news about Zhuhai Rundu Pharmaceutical Co., Ltd.

Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Final Cash Dividend on A Shares for 2023, Payable on 31 May 2024	May. 20	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 26	CI
Rundu Pharmaceutical's Rabeprazole Sodium Tablets Chosen for China's Centralized Procurement	Nov. 09	MT
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Zhuhai Rundu Pharma Gets Supplementary Application Approval For Hypertension Drug	23-07-26	MT
Rundu Pharmaceutical Gets Nod to Market Raw Drug Material	23-07-13	MT
Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Final Cash Dividend for 2022, Payable on 31 May 2023	23-05-19	CI
Tianyu Pharmaceutical Unit Gets Approval to Market Hypertension Drug in China	23-05-09	MT
Zhuhai Rundu Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022	23-04-27	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Management Appointments	23-03-15	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Rundu Pharmaceutical Unit Wins Drug Production License	22-10-04	MT
Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021	22-05-12	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Proposes Cash Dividend for 2021	22-04-20	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-19	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-18	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-25	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Dividend for 2020, Payable on 28 May 2021	21-05-19	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Announces Final Dividend Profit Distribution Proposal for 2020	21-04-23	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Announces to Implement Final Cash Distribution Plan for 2019, Payable on 09 June 2020	20-06-02	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Cash Dividend	20-05-18	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Proposes Final Cash Dividend on A Share for 2019	20-04-17	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Election of Directors	20-03-31	CI

Chart Zhuhai Rundu Pharmaceutical Co., Ltd.

Duration

Period

Chart Zhuhai Rundu Pharmaceutical Co., Ltd.

More charts

Zhuhai Rundu Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of chemical medicine preparations, chemical medicine raw materials and pharmaceutical intermediates. The Companyâs products cover the fields of cardio-cerebral blood vessels, digestion and anesthesia, among others.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHUHAI RUNDU PHARMACEUTICAL CO., LTD.	-13.86%	492M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B